PCI Biotech Holding - Earnings Release 2016

PCI Biotech: Second quarter and first half year 2016 results

Oslo, 30 August 2016.

Please find enclosed the financial report and presentation for second quarter

Highlights

* Granted Orphan Drug Designation of fimaporfin for treatment of bile duct

cancer in EU

* Commissioned independent expert evaluation of the early promising response

data - results expected Q3 2016

* Lancet Oncology publication of the fimaporfin (Amphinex) first-in-man phase

I study - with independent expert commentary

* fimaVacc ready for clinical validation - a major milestone towards potential

commercialization

* Initiated first research collaboration with commercial entity for fimaVacc

A presentation will be held today, Tuesday 30 August 2016, at Oslo Cancer

Cluster Innovation Park.

Time: Tuesday August 30 2016, 09.00-10.00 hrs.

Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster

Innovation Park, Ullernchausséen 64, Oslo.

Kind regards,

Per Walday

CEO

Mobil: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

AI assistant